People
Gilmore O’Neill, formerly Biogen’s senior vice president, late-stage clinical development, jumped ship and will be Sarepta Therapeutics’ chief medical officer.
In a recent interview, Ron Cohen, chief executive officer of Acorda Therapeutics, indicated that if the company lost its appeals over patent lawsuits for its Ampyra for multiple sclerosis, there would not be layoffs in its sales force.
After two of Allergan’s investors, Appaloosa Management and Senator Investment Group, wrote to the company’s board asking that Brent Saunders’ duties be split up, legendary investor Carl Icahn appears to be building a position in the company—again.
Actor, director and advocate Rob Reiner opened the third day of the 2018 BIO International Convention.
Unity Biotechnology has raised $222 million in venture capital, raised $85 million in an initial public offering (IPO) in May, and has a value of $700 million. All without having a product to sell.
Appaloosa Management’s David Tepper and Senator Investment Group’s Douglas Silverman sent a letter to Allergan’s board of directors yesterday asking—or demanding—that the company split the roles of chief executive officer and chairman.
South San Francisco-based Senti Biosciences is getting a new Chief Financial Officer and Chief Business Officer. Former Sangamo Therapeutics Senior Vice President and Chief Business Officer Curt Herberts will join Senti later this month.
Robin Roberts, ABC’s Good Morning America journalist and anchor, kicked off the 2018 BIO International Convention in Boston with her keynote address.
Portola Pharmaceuticals’ chief executive officer, William Lis, plans to retire as both chief executive and board member.
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
PRESS RELEASES